Interferon-related secretome from direct interaction between immune cells and tumor cells is required for upregulation of PD-L1 in tumor cells

References

[1] Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465

[2] Chen J, Feng Y, Lu L, Wang H, Dai L, Li Y, Zhang P (2012) Interferon-gamma induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. Immunobiology 217:385–393

[3] Cho YA, Yoon HJ, Lee JI, Hong SP, Hong SD (2011) Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol 47:1148–1153

[4] Ejlerskov P, Hultberg JG, Wang J, Carlsson R, Ambjorn M, Kuss M, Liu Y, Porcu G, Kolkova K, Friis Rundsten C (2015) Lack of neuronal IFN-β-IFNAR causes lewy body-and parkinson's disease-like dementia. Cell 163:324–339

[5] Furuta J, Inozume T, Harada K, Shimada S (2014) CD271 on melanoma cell is an IFN-γ-inducible immunosuppressive factor that mediates downregulation of melanoma antigens. J Investig Dermatol 134:1369–1377

[6] Gowrishankar K, Gunatilake D, Gallagher SJ, Tiffen J, Rizos H, Hersey P (2015) Inducible but not constitutive expression of PDL1 in human melanoma cells is dependent on activation of NF-κB. PLoS One 10:e0123410

[7] Hou J, Yu Z, Xiang R, Li C, Wang L, Chen S, Li Q, Chen M, Wang L (2014) Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. Exp Mol Pathol 96:284–291

[8] Jin YH, Hou W, Kang HS, Koh CS, Kim BS (2013) The role of interleukin-6 in the expression of PD-1 and PDL-1 on central nervous system cells following infection with Theiler's murine encephalomyelitis virus. J Virol 87:11538–11551

[9] Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348:74–80

[10] Kronig H, Kremmler L, Haller B, Englert C, Peschel C, Andreesen R, Blank CU (2014) Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment. Eur J Haematol 92:195–203

[11] Lastwika KJ, Wilson W 3rd, Li QK, Norris J, Xu H, Ghazarian SR, Kitagawa H, Kawabata S, Taube JM, Yao S (2016) Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung Cancer. Cancer Res 76:227–238

[12] McClanahan F, Riches JC, Miller S, Day WP, Kotsiou E, Neuberg D, Croce CM, Capasso M, Gribben JG (2015) Mechanisms of PDL1/PD-1-mediated CD8 T-cell dysfunction in the context of agingrelated immune defects in the Eμ-TCL1 CLL mouse model. Blood 126:212–221

[13] Noh H, Hu J, Wang X, Xia X, Satelli A, Li S (2015) Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells. Cell Commun Signal 13:14

[14] Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454

[15] York AG, Williams KJ, Argus JP, Zhou QD, Brar G, Vergnes L, Gray EE, Zhen A, Wu NC, Yamada DH (2015) Limiting cholesterol biosynthetic flux spontaneously engages type I IFN signaling. Cell 163:1716–1729

RIGHTS & PERMISSIONS

2016 The Author(s) 2016. This article is published with open access at Springerlink.com and journal.hep.com.cn